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Percutaneous vesicoamniotic shunting versus conservative 
management for fetal lower urinary tract obstruction 
(PLUTO): a randomised trial
Rachel K Morris, Gemma L Malin, Elisabeth Quinlan-Jones, Lee J Middleton, Karla Hemming, Danielle Burke, Jane P Daniels, Khalid S Khan, 
Jon Deeks, Mark D Kilby, for the Percutaneous vesicoamniotic shunting in Lower Urinary Tract Obstruction (PLUTO) Collaborative Group
Summary
Background Fetal lower urinary tract obstruction (LUTO) is associated with high perinatal and long-term childhood 
mortality and morbidity. We aimed to assess the eﬀ ectiveness of vesicoamniotic shunting for treatment of LUTO.
Methods In a randomised trial in the UK, Ireland, and the Netherlands, women whose pregnancies with a male fetus 
were complicated by isolated LUTO were randomly assigned by a central telephone and web-based randomisation 
service to receive either the intervention (placement of vesicoamniotic shunt) or conservative management. Allocation 
could not be masked from clinicians or participants because of the invasive nature of the intervention. Diagnosis was 
by prenatal ultrasound. The primary outcome was survival of the baby to 28 days postnatally. All primary analyses 
were done on an intention-to-treat basis, but these results were compared with those of an as-treated analysis to 
investigate the eﬀ ect of a fairly large proportion of crossovers. We used Bayesian methods to estimate the posterior 
probability distribution of the eﬀ ectiveness of vesicoamniotic shunting at 28 days. The study is registered with the 
ISRCTN Register, number ISRCTN53328556.
Findings 31 women with singleton pregnancies complicated by LUTO were included in the trial and main analysis, with 
16 allocated to the vesicoamniotic shunt group and 15 to the conservative management group. The study closed early 
because of poor recruitment. There were 12 livebirths in each group. In the vesicoamniotic shunt group one intrauterine 
death occurred and three pregnancies were terminated. In the conservative management group one intrauterine death 
occurred and two pregnancies were terminated. Of the 16 pregnancies randomly assigned to vesicoamniotic shunting, 
eight neonates survived to 28 days, compared with four from the 15 pregnancies assigned to conservative management 
(intention-to-treat relative risk [RR] 1·88, 95% CI 0·71–4·96; p=0·27). Analysis based on treatment received showed a 
larger eﬀ ect (3·20, 1·06–9·62; p=0·03). All 12 deaths were caused by pulmonary hypoplasia in the early neonatal period. 
Sensitivity analysis in which non-treatment-related terminations of pregnancy were excluded made some slight changes 
to point estimates only. Bayesian analysis in which the trial data were combined with elicited priors from experts 
suggested an 86% probability that vesicoamniotic shunting increased survival at 28 days and a 25% probability that it 
had a large, clinically important eﬀ ect (deﬁ ned as a relative increase of 55% or more in the proportion of neonates who 
survived). There was substantial short-term and long-term morbidity in both groups, including poor renal function—
only two babies (both in the shunt group) survived to 2 years with normal renal function. Seven complications occurred 
in six fetuses from the shunt group, including spontaneous ruptured membranes, shunt blockage, and dislodgement. 
These complications resulted in four pregnancy losses.
Interpretation Survival seemed to be higher in the fetuses receiving vesicoamniotic shunting, but the size and 
direction of the eﬀ ect remained uncertain, such that beneﬁ t could not be conclusively proven. Our results suggest 
that the chance of newborn babies surviving with normal renal function is very low irrespective of whether or not 
vesicoamniotic shunting is done.
Funding UK National Institute of Health Research, Wellbeing of Women, Hannah Eliza Guy Charity (Birmingham 
Children’s Hospital Charity).
Introduction
Fetal lower urinary tract or bladder outﬂ ow obstruction 
(LUTO) can lead to abnormal renal development, the 
results of which persist into childhood. The two most 
common congenital malformations to cause LUTO are 
posterior urethral valves1 and urethral atresia.2 Severe 
prenatal renal impairment is often associated with clinic-
ally signiﬁ cant oligohydramnios. Such an ultrasound 
presen tation, between 16 and 24 weeks, is associated with a 
high prevalence of pulmonary hypoplasia, resulting in 
high perinatal mortality and morbidity.3–5
LUTO is usually diagnosed at 20 weeks of gestation, 
when most pregnant women in developed countries have 
a routine detailed fetal anomaly scan. Typical ultrasound 
features in the fetus are megacystis (enlarged bladder with 
a dilated proximal urethra) and bilateral hydronephrosis 
with or without renal parenchymal cystic appearances 
(cystic kidney disease). Such ultrasound features are 
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generally associated with clinically signiﬁ cant oligo-
hydram nios. The occurrence of both renal cystic change 
and oligohydramnios with mega cystis is highly predictive 
of a urethral obstructive origin.6 Such prenatal ultrasound 
ﬁ ndings are of little value in the diﬀ erentiation of posterior 
urethral valves from other causes of LUTO,6,7 and the ﬁ nal 
underlying pathological diagnosis is often not conﬁ rmed 
until the postnatal period. Some researchers have 
advocated fetal urinalysis to allow fetal triage and the 
allocation of risk of postnatal renal damage prospectively.8–10 
However, investigators of a systematic review11 noted that 
the overall diagnostic accuracy of such testing is low and 
could not be relied on in case selection for treatment.
Bladder drainage by serial vesicocentesis or by con-
tinuous drainage into the amniotic cavity by placement 
of a vesicoamniotic shunt has been used to relieve fetal 
LUTO by bypassing the urethral blockage. Prenatal 
vesicoamniotic shunting attempts to reduce or avoid 
renal parenchymal damage and chronic oligo hydramnios 
that can adversely aﬀ ect pulmonary develop ment.12–14 
Our group’s previous systematic review15 to assess the 
eﬀ ective ness of bladder drainage (vesico amniotic shunt-
ing or vesicocentesis) showed that fetal bladder drainage 
increased survival (pooled odds ratio [OR] for perinatal 
survival 2·53, 95% CI 1·08–5·93). However, none of the 
studies identiﬁ ed in the systematic review were 
randomised trials and so the potential for bias in these 
results is substantial. Some investigators have suggested 
that tremendous improve ments in fetal selection for 
vesicoamniotic shunting have led to increased survival.16 
The results of our review15 suggested that the poor 
outlook group might beneﬁ t more from shunting than 
would babies who have a better outlook, and that a false-
positive diagnosis of LUTO is made in 25% of those 
babies with a better outlook.17
We aimed to assess the eﬀ ect on survival of vesico-
amniotic shunting compared with conservative manage-
ment in fetuses with LUTO.
Figure 1: Trial proﬁ le
Normal renal function is deﬁ ned as serum creatinine less than 50 μmol/L; mild renal impairment is deﬁ ned as serum creatinine of 50 μmol/L or more, not requiring 
medical treatment; moderate renal impairment is deﬁ ned as serum creatinine of 50 μmol/L or more, requiring medical treatment; end-stage renal failure is deﬁ ned as 
need for transplant or dialysis. TOP=termination of pregnancy. *Two treatment related TOPs occurred secondary to spontaneous rupture of membranes after shunt 
insertion at 17 and 22 weeks. †Parental decision at 18–25 weeks. ‡After spontaneous rupture of membranes at 16 weeks. §Due to pulmonary hypoplasia.
31 pregnancies randomly assigned
12 livebirths 12 livebirths
16 allocated to percutaneous vesicoamniotic shunting
 13 received fetal shunt
 3 received conservative management
2 treatment-related TOPs* 
1 non-treatment-related TOP†
1 treatment-related intrauterine death‡
2 TOPs† 
1 intrauterine death at 18 weeks
4 neonatal deaths within 24 h§
1 died from renal failure at 10 months
7 neonatal deaths within 24 h§
1 neonatal death at 3 days§
15 allocated to conservative management
 13 received conservative management
 2 received fetal shunt
8 alive at 28 days
 2 with normal renal function
 2 with mild renal impairment
 4 with moderate renal impairment
4 alive at 28 days
 1 with mild renal impairment
 2 with moderate renal impairment
 1 with end-stage renal failure
1 died from renal failure at 7 weeks 
7 alive at 1 year
 2 with normal renal function
 1 with mild renal impairment
 4 with moderate renal impairment
3 alive at 1 year
 3 with moderate renal impairment
7 alive at 2 years
 2 with normal renal function
 5 with moderate renal impairment
3 alive at 2 years
 2 with moderate renal impairment
 1 with end-stage renal failure
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Methods
Study design and participants
We undertook a randomised, international, multicentre 
trial (Percutaneous vesicoamniotic shunting for fetal 
Lower Urinary Tract Obstruction [PLUTO]). Parallel to 
the trial were a register of eligible pregnancies with 
LUTO for which randomisation was not possible 
because of either patient or clinician preference, and an 
anonymous register of terminations of eligible preg-
nancies. Inclusion criteria were consenting pregnant 
women who had a singleton male fetus with an 
ultrasound diagnosis of LUTO (diagnosed on the basis 
of the visualisation of an enlarged bladder and dilated 
proximal urethra, bilateral or unilateral hydronephrosis, 
and cystic parenchymal renal disease6,18) about whom 
the clinician was uncertain as to the optimum 
management.
Fetuses with additional major structural or chromosomal 
anomalies were excluded. Female fetuses were also 
excluded from the trial because they are more likely than 
male fetuses to have a complex cause behind their 
diagnosis and a very poor outlook. No eligibility criteria 
related to gestational age or volume of amniotic ﬂ uid. All 
participants provided written informed consent. The 
participants were counselled and given written information 
about the risks of the procedure: miscarriage, prelabour 
rupture of membranes and premature labour, chorio-
amnionitis, and shunt blockage or migration. The PLUTO 
trial received ethics approval from Nottingham Research 
Ethics Committee 2 (Jan 21, 2005; reference 04/Q2404/89). 
The protocol was published19 and no substantial changes 
were made during the course of the study.
Randomisation and masking
21 fetal medicine centres in England, Scotland, Ireland, 
and the Netherlands participated in the study, seven of 
which (from England, Scotland, and the Netherlands) 
recruited women to the trial. Pregnancies were allocated 
to intervention (placement of vesicoamniotic shunt) 
or conservative management by a central telephone 
and web-based randomisation service provided by 
the University of Birmingham Clinical Trials Unit 
(Birming ham, UK). Allocations were concealed until 
all baseline characteristics for the individual partici-
pant had been recorded. We used a computerised 
minimisation pro cedure to achieve balance between 
groups for gestational age at diagnosis (<24 or 
≥24 weeks), volume of amniotic ﬂ uid (≤5th centile or 
>5th centile), and age of mother (<20, 20–35, or 
>35 years). Because of the nature of the intervention, 
clinician and participant masking was not possible.
Procedures
For vesicoamniotic shunting, participants were oﬀ ered 
sedation, and prophylactic antibiotics were given 2 h 
before the procedure. The fetus and fetal bladder were 
visualised continuously by high-quality, high-resolution, 
real-time 2D ultrasound (Siemens S2000 or equivalent). 
With a sterile, minimum-touch technique, a vesico-
amniotic pigtail catheter was inserted per cutaneously 
with either the King’s College/Rocket introducer or the 
Vesicoamniotic 
shunt
(n=16)
Conservative 
management 
(n=15)
Maternal age (years) 27 (23–33) 28 (26–33)
Maternal age group*
<20 years 2 0
20–35 years 12 12
>35 years 2 3
Ethnic origin
White 13 13
Asian 2 1
Black 1 1
Gestational age (weeks) 20 (16–22) 21 (19–22)
Gestational age group*
<24 weeks 13 14
≥24 weeks 3 1
Amniotic ﬂ uid volume maximum 
pool depth (cm)
1·6 (0–2·9) 1·0 (0·2–2·9)
Amniotic ﬂ uid volume, by centile*†
<5th centile 10 9
≥5th centile 6 6
Renal pelvis dilatation, left (mm) 7·4 (5·0–14) 7·3 (5·0–9·0)
Renal pelvis dilatation, right (mm) 8 (4·8–10) 8·6 (5·0–11)
Anteroposterior renal pelvis dilatation diameter >90th centile‡
Bilateral 13 12
Unilateral 2 0
Neither 0 1
Not recorded 1 2
Renal pelvis severe hydronephrosis 
>1·5 cm§
Bilateral 1 0
Unilateral 1 1
Neither 13 13
Not recorded 1 1
Macrocystic renal appearance
Bilateral 0 1
Unilateral 2 4
Neither 14 10
Renal echogenicity
Bilateral 2 4
Unilateral 3 3
Neither 7 5
Not recorded 4 3
Bladder wall thickness >3 mm
Yes 6 9
No 8 5
Not recorded 2 1
Data are n or median (IQR). *Stratiﬁ cation variable and predeﬁ ned subgroup. †See 
reference 23. ‡See reference 24. §See reference 25. 
Table 1: Baseline characteristics of mothers and fetuses
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Harrison shunting set, according to clinician preference. 
Optimum placement of the shunt (with the distal end in 
the fetal bladder and the proximal end in the amniotic 
cavity) and fetal viability were conﬁ rmed immediately 
and at several hours post-procedure.
Follow-up ultrasound scans were arranged at the 
clinicians’ discretion, but were usually no less frequent 
than every 4 weeks. All investigators had special training 
in fetal medicine (recognised by the UK Royal College of 
Obstetrics and Gynaecology or international equivalent). 
UK and Ireland investigators without demonstrable 
competence in ultrasound-guided vesicoamniotic shunt 
insertion referred women to the Fetal Medicine Centre at 
Birmingham Women’s Hospital (Birmingham, UK). 
Leiden University Medical Centre (Leiden, Netherlands) 
received referrals from other hospitals across the 
Netherlands. All vesicoamniotic shunts were inserted 
within 7 days of random assignment. Conservative 
management was standard care (no intervention) with 
follow-up ultrasound scans arranged at the clinicians’ 
discretion, but usually no less frequently than every 
4 weeks.
The primary outcome measure was survival to 28 days 
after birth. Secondary outcomes were survival at 1 and 
2 years, and renal function at 28 days, 1 year, and 2 years 
(measured by serum creatinine, renal ultrasound 
appear ance, and evidence of renal impairment [need for 
medical treatment, dialysis, or transplantation]). Data 
for serious adverse events were obtained, including 
preg nancy loss before 24 weeks, premature rupture of 
membranes, chorioamnionitis, damage to maternal 
uterus or other organs, damage to fetal organs, and 
migration of stent.
Statistical analysis
The planned sample size for the trial was based on our 
group’s previous meta-analysis of observational studies,15 
reported at the time we were designing the trial, in 
which we noted an improvement in survival with 
vesicoamniotic shunting from 39% to 61% (equivalent to 
a relative risk [RR] of 1·55). At 80% power and α=0·05, 
75 pregnancies in each study group would be suﬃ  cient 
to detect such a diﬀ erence.
We calculated RRs and their 95% CIs by standard 
normal approximation methods for the primary out-
come of survival at 28 days, with signiﬁ cance assessed 
by two-sided Fisher’s exact test. All primary analyses 
were done on an intention-to-treat basis, but these were 
compared with an as-treated analysis to investigate the 
eﬀ ect of a fairly large proportion of crossovers. Intra-
uterine deaths and terminations of pregnancy were 
included in the analysis and classed as a death in the 
primary analysis, although we did a sensitivity analysis 
in which non-treatment-related terminations (parent 
choice) were excluded. Analyses of livebirths and 
survival to 1 year and 2 years were done as per the 
Intention-to-treat analysis As-treated analysis*
Vesico amniotic 
shunt
Con servative 
manage ment
RR (95% CI) p value† Vesico amniotic 
shunt
Con servative 
manage ment
RR (95% CI) p value†
Livebirths 12/16 12/15 0·94 (0·64–1·37) >0·99 11/15 13/16 0·90 (0·61–1·33) 0·69
28 days 8/16 4/15 1·88 (0·71–4·96) 0·27 9/15 3/16 3·20 (1·06–9·62) 0·03
1 year 7/16 3/15 2·19 (0·69–6·94) 0·25 8/15 2/16 4·27 (1·07–16·96) 0·02
2 years 7/16 3/15 2·19 (0·69– 6·94) 0·25 8/15 2/16 4·27 (1·07–16·96) 0·02
Data are n/N, unless otherwise indicated. Primary outcome was survival to 28 days. Terminations of pregnancy were included as treatment failures. RR=relative risk. *Three 
pregnancies were allocated to vesicoamniotic shunt but received conservative management, and two pregnancies were allocated conservative management but received 
vesicoamniotic shunt (non-randomised comparison). †Two-sided Fisher’s exact test.
Table 2: Survival outcomes
 Intention-to-treat analysis As-treated analysis†
Vesicoamniotic 
shunt
Conservative 
management
RR (95% CI) p value‡ Vesicoamniotic 
shunt
Conservative 
management
RR (95% CI) p value‡
Livebirths 12/15 12/13 0·87 (0·64–1·17) 0·60 11/14 13/14 0·85 (0·62–1·15) 0·60
28 days 8/15 4/13 1·73 (0·68–4·45) 0·28 9/14 3/14 3·00 (1·02–8·80) 0·05
1 year 7/15 3/13 2·02 (0·65–6·26) 0·25 8/14 2/14 4·00 (1·03–15·60) 0·05
2 years 7/15 3/13 2·02 (0·65–6·26) 0·25 8/14 2/14 4·00 (1·03–15·60) 0·05
Data are n/N, unless otherwise indicated. Primary outcome was survival to 28 days. RR=relative risk. *Two non-treatment-related terminations of pregnancy were allocated 
to the conservative management group, one to the vesicoamniotic shunt group. †Three pregnancies were allocated to vesicoamniotic shunt but received conservative 
management, and two pregnancies were allocated to conservative management but received vesicoamniotic shunt (non-randomised comparison). ‡Two-sided Fisher’s exact 
test (the CIs and the p value seem incompatible because of the sparse data having a diﬀ erent eﬀ ect under the diﬀ erent statistical assumptions made in their calculation 
[normal approximation vs exact method]).
Table 3: Sensitivity analysis excluding non-treatment-related terminations of pregnancy*
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primary outcome. Formal statistical analysis was not 
attempted for the other outcome measures, nor were 
subgroup analyses or covariate adjustments, because of 
the small number of participants recruited. We have 
reported summary statistics (means with SDs or 
medians with IQRs) or individual values for these 
outcomes as appropriate.
Using a questionnaire, we elicited expert opinions on 
beneﬁ ts of vesicoamniotic shunting relative to con-
ventional treatment from fetal medicine specialists, 
paediatric nephrologists, and paediatric urologists to 
provide informative Bayesian priors for survival to 
28 days. The elicited opinions were pooled across 
experts to create an informative prior distribution. We 
used Bayesian methods to estimate the posterior 
probability distribution of the eﬀ ectiveness of vesico-
amniotic shunting at 28 days (a logistic model) with 
both the informative experts’ prior distribution and a 
non-informative prior (centred at the value of no eﬀ ect, 
with very large variance [100²]).20 The analysis with non-
informative priors replicates the frequentist analysis to 
allow for additional probabilistic inter pretation of the 
results. We also used a Bayesian Cox proportional 
hazards method to model survival to Dec 1, 2012, with 
non-informative priors (informative priors were not 
elicited for survival beyond 28 days). The Cox 
proportional hazards model was stratiﬁ ed from 
conception to 36·5 weeks (around the time of birth) 
and from 36·5 weeks onwards. To make the estimate 
on the hazard ratio (HR) scale consistent with the RR 
estimates of relative survival (insofar as both HR>1 and 
RR>1 favour vesicoamniotic shunting), the HR 
compares the hazard on conservative management 
with the intervention.
The probability of vesicoamniotic shunting increasing 
survival (RR or HR >1) and the probability of such an 
intervention substantially increasing survival at 28 days 
after birth (RR or HR >1·55, the diﬀ erence the trial was 
powered to detect had recruitment targets been 
met) were calculated from posterior distributions. All 
Bayesian analyses were done with WinBUGS,20 with 
200 000 iterations after allowing for a 10 000-iteration 
burn-in and checking for convergence with several 
common measures. Summary estimates reported are 
medians with 95% credible intervals (CrIs). All Bayesian 
analyses were done on an intention-to-treat basis. 
Additional Bayesian analyses (eg, as treated) are 
reported elsewhere.21
This trial is registered with the ISRCTN Register, 
number ISRCTN53328556.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Vesicoamniotic shunt Conservative management
Livebirths
n 12 12
Days from randomisation to delivery 93 (69–118) 104 (94–112)
Gestational age at delivery (days) 249 (234–263) 255 (242–262)
Preterm labour (<37 weeks) 7 8
Vaginal delivery 8 7*
Mean birthweight, kg (SD) 2·8 (0·5) 2·8 (0·4)
Birthweight <10th centile 5 4
Admitted to neonatal ICU or children’s 
hospital
10 10
Required ventilation 6† 7‡
Required treatment for renal 
impairment
4† 3‡
Perinatal (about 28 days)
n 8 4
Required surgery in perinatal period 5 3
Still an inpatient 3† 2
Serum creatinine, μmol/L 29, 29, 88, 96, 105, 108, 
119, 342
70, 126, 449, 620
Renal function§
Normal 2 0
Mild impairment 2 1
Moderate impairment 4 2
End-stage renal failure 0 1
1 year
n 7 3
Required surgery from perinatal period 
to 1 year
6 0
Days in hospital 0, 1, 3, 20, 25, 84, 102 22, 39, NR
Weight <10th centile 4† 2†
Serum creatinine, μmol/L 34, 37, 58, 64, 81, 88, 226 60, 60, 501
Renal function§
Normal 2 0
Mild impairment 1 0
Moderate impairment 4 3
2 years
n 7 3
Required surgery between 1 and 2 years 4 1
Days in hospital 0, 1, 5, 19, 30, 37, 116 23, 37, 40
Weight <10th centile 3‡ 2
Serum creatinine, μmol/L 65, 34, 87, 227, 60, 74, NR 502, 61, 72
Renal function§
Normal 2 0
Mild 0 0
Moderate 5 2
End-stage renal failure 0 1¶
Cognitive impairment 1 serious None reported abnormal||
Data are n, median (IQR), or a list of individual values, unless otherwise indicated. ICU=intensive care unit. 
NR=not recorded (where individual values shown). *Includes one vaginal breech. †One baby did not have weight 
recorded. ‡Two babies did not have weight recorded. §Normal renal function is defined as serum creatinine less than 
50 μmol/L; mild impairment is deﬁ ned as serum creatinine of 50 μmol/L or more, not requiring medical treatment; 
moderate impairment is deﬁ ned as serum creatinine of 50 μmol/L or more, requiring medical treatment; end-stage 
renal failure is deﬁ ned as need for transplant or dialysis. ¶On transplant register. ||Not all infants were investigated for 
cognitive impairment.
Table 4: Other outcomes
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Results
Seven of the 21 participating centres recruited women to 
the trial. 31 women with singleton pregnancies com-
plicated by LUTO agreed to be randomly assigned to a 
trial group between Oct 2, 2006, and Oct 11, 2010. 
Follow-up for the 2-year outcome was completed on 
Sept 21, 2012. The planned sample size of the trial was 150, 
but enrolment was stopped after 31 women had been 
assigned because of diﬃ  culties with recruitment. The 
main barriers were issues with achievement of sponsor-
ship and indemnity for international centres, slow 
approval for UK centres, a higher proportion of parents 
than expected choosing for termination of pregnancy 
(n=68), lower prevalence of disease than reported in the 
scientiﬁ c literature,22 and a high proportion of parents and 
clinicians choosing to enter a registry rather than be 
randomly assigned to a trial group (n=45). The registry 
data will be reported elsewhere.21 Figure 1 shows the 
trial proﬁ le. Complete follow-up for all participants was 
available to 2 years (range 2·2–5·6).
Baseline characteristics of participants were well 
balanced between trial groups (table 1). The median age 
of mothers in the trial was 28 years (IQR 23–33), with 
presentation at a median gestation of 21 weeks (18–22), 
with 27 of 31 at less than 24 weeks’ gestation at the time of 
LUTO diagnosis. Most fetuses had oligohydramnios 
(table 1; maximum pool depth range in shunt group 
0·0–4·4 cm and in conservative management group 
0·0–4·9 cm). Seven fetuses underwent vesicocentesis 
and fetal urinalysis before shunt insertion, ﬁ ve or which 
had a prospective designation of good outlook and two a 
poor outlook.26 Four fetuses in the shunt group and ﬁ ve in 
the conservative management group were prospectively 
karyotyped and all had normal male karyotype. All 31 were 
conﬁ rmed as male fetuses postnatally and had no 
dysmorphic features of chromosomal anomaly. 15 women 
underwent a shunt procedure; six were done at 
Birmingham Women’s Hospital, one at Newcastle Royal 
Victoria Inﬁ rmary (Newcastle, UK), three at Liverpool 
Women’s Hospital (Liverpool, UK), one at St George’s 
Proportion 
aﬀ ected*
Outcome
Spontaneous 
rupture of 
membranes after 
shunt insertion
3/15 Intrauterine death at 16 weeks’ 
gestation (n=1); pregnancy aﬀ ected by 
chorioamnionitis and parents chose to 
terminate at 17–22 weeks’ gestation 
(n=2)
Dislodged 3/15 Spontaneous rupture of membranes 
with chorioamnionitis and parents 
chose to terminate at 17 weeks’ 
gestation (n=1); subsequent pregnancy 
urinary ascites and neonatal death due 
to pulmonary hypoplasia (n=1); shunt 
reinserted, subsequent preterm labour 
at 26 weeks’ gestation, alive at 28 days 
(n=1)
Blocked 1/15 Parents chose to terminate at 19 weeks’ 
gestation (not related to treatment; 
persistent fetal bradycardia; n=1)
Four of 15 pregnancies were lost in the vesicoamniotic shunt group (three from 
spontaneous rupture of membranes and one after blockage). *Six were aﬀ ected in 
total, with some having more than one complication.
Table 5: Complications of vesicoamniotic shunting
0·2 0·5 1·0 1·55 2 5 10
Pr
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sit
y
Probability of decreased survival=0·21 Probability of increased survival=0·79
Probability of substantially increased 
survival=0·15
A
0·2 0·5 1·0 1·55 2 5 10
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y
Probability of decreased survival=0·14 Probability of increased survival=0·86
Probability of substantially increased 
survival=0·25
B
0·2 0·5 1·0 1·55 2 5 10
Pr
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en
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y
Relative risk of survival
Probability of decreased survival=0·08
Probability of increased 
survival=0·92
Probability of substantially 
increased survival=0·67
C
Figure 2: Results of Bayesian analysis
Bayesian prior and posterior estimates of relative risk of survival to age 28 days. The prior distribution (A) was 
obtained by eliciting prior distributions from 52 experts, averaging the distributions, and ﬁ tting a normal distribution. 
The posterior distribution (B) is based on combining the elicited prior with the intention-to-treat results. The posterior 
distribution (C) is based on combining a non-informative prior with the intention-to-treat results.
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Hospital (London, UK), and four at Leiden University 
Medical Centre. Five operators inserted the shunts; 10 of 
the 15 insertions used the Harrison shunt and ﬁ ve the 
Rocket shunt.
Three of the 16 pregnancies randomly assigned to 
vesicoamniotic shunting did not receive the intervention, 
and two of the 15 randomly assigned to conservative 
management had shunting. Indications for not receiving 
the allocated shunt were that parents withdrew consent 
after assignment (to treatment, but not follow-up), 
that the woman or the fetus had a contraindication to 
shunting after assignment, or that the clinician decided 
that insertion of a shunt was inappropriate because of 
poor fetal condition. The two cases in which women 
randomly assigned to conservative management received 
a shunt were both due to deterioration in the clinical 
situation (principally anhydramnios) and the clinician 
believing that shunting was appropriate. In three cases 
(one in the shunt group and two in the conservative 
management group) parents decided on termination of 
the pregnancy between 18 and 25 weeks because of 
perceived poor outlook by the health-care professionals 
and parents. These decisions were believed to be un-
related to the treatment.
12 livebirths occurred in each trial group. In the shunt 
group there was one intrauterine death at 16 weeks after 
shunt insertion and three pregnancies were terminated 
(two of which were related to treatment and followed 
spontaneous rupture of membranes after shunt inser-
tion, and one of which was by parental choice; ﬁ gure 1). 
In the conservative management group three pregnancies 
resulted in fetal loss, with one intrauterine death at 
18 weeks and two terminations of pregnancy (by parental 
choice) at 18 and 24 weeks.
The median interval between random assignment and 
delivery was 93 days (IQR 69–118) in the shunt group and 
104 days (94–112) in the conservative management group. 
The median interval for both groups combined was 
101 days (89–112). No signiﬁ cant diﬀ erence in gestational 
age of delivery was seen between the two groups 
(34·6 weeks [IQR 33·4–37·2] in the shunt group and 
36·4 weeks [34·5–37·4] in the conservative management 
group). Two babies (both in the shunt group) were 
delivered preterm between 24 and 32 weeks.
Of the fetuses assigned to the shunt group, half 
survived to 28 days compared with about a quarter of 
those assigned to conservative management (table 2). 
All 12 neonatal deaths were caused by pulmonary 
hypoplasia; 11 occurred within the ﬁ rst 24 h after birth, 
and the other at 3 days. In the as-treated analysis, about 
two-thirds of the participants given a vesicoamniotic 
shunt survived to 28 days compared with about a ﬁ fth 
given conservative management (table 2). Sensitivity 
analysis that excluded non-treatment-related termi-
nations of pregnancy made some slight changes only to 
point estimates (table 3).
One baby in each trial group subsequently died before 
age 1 year because of renal failure (ﬁ gure 1). RR estimates 
for survival at 1 year were close to those seen at 28 days 
(tables 2, 3). No deaths occurred between age 1 year and 
age 2 years, so the RR estimates for survival at 2 years are 
the same as those for 1 year.
Most livebirths were preterm (less than 37 weeks’ 
gestational age) and most were admitted to a neonatal 
intensive care unit or children’s hospital (table 4). Some 
neonates required ventilation or immediate treatment for 
renal impairment (table 4). Of the 12 babies who survived 
to 28 days, only two did not have any renal impairment 
(serum creatinine <50 μmol/L and did not need medical 
treatment, dialysis, or transplantation). Both babies were 
among those who received a shunt and were also the only 
two babies without renal impairment at the 1-year follow-
up. No diﬀ erence in survival with normal renal function 
was seen in the as-treated analysis at 28 days or at 1 year 
(table 4). At age 2 years one baby in the shunt group had 
progressed from mild to moderate impairment and one 
baby in the conservative management group had pro-
gressed from moderate impairment to end-stage renal 
failure (requiring dialysis and awaiting transplantation). 
At 2 years, one baby in the shunt group had serious 
cognitive and motor impairment.
Abnormal changes were diagnosed in all 12 perinatal 
survivors, and a post mortem was done for three of the 
neonatal deaths (one in the shunt group and two in the 
conservative management group). The diagnoses were 
nine cases of posterior urethral valves (ﬁ ve in the shunt 
group and four in the conservative management group), 
ﬁ ve cases of urethral atresia (four in the shunt group and 
one in the conservative management group), and one 
Figure 3: Kaplan-Meier estimates of survival from conception to end of follow-up
Vertical dashes on the lines represent censored observations, either through parental choice to terminate 
pregnancy (before 36·5 weeks) or end of follow-up. Hazard ratios (HRs) were calculated for the period 
0–36·5 weeks and from 36·5 weeks to the end of follow-up (conditional on survival to 36·5 weeks). These HRs are 
Bayesian estimates based on non-informative priors. The hazard rate comparison is of conservative management 
versus vesicoamniotic shunt, such that the interpretation of HRs greater than 1 as being indicative of beneﬁ t is 
consistent with the interpretation of the relative risk estimates. CrI=credibility interval. 
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case of urethral syrinx that caused obstruction (in the 
conservative management group). Of seven cases that 
were pregnancy losses (terminations or intrauterine 
deaths), three had a post-mortem examin ation, which 
conﬁ rmed urethral atresia in two fetuses and of posterior 
urethral valves in one. Thus in 13 cases no such changes 
were seen; four of these were miscarriages and nine were 
neonatal deaths attributed to pulmonary hypoplasia.
All babies with posterior urethral valves underwent 
urethral valve resection in the perinatal period (up to 
6 weeks postnatally), and all those with urethral atresia had 
a vesicostomy. Six of the ten survivors (all in the shunt 
group) required some sort of renal surgery at 1 year 
(table 4). One baby required both valve resection and a 
vesicostomy in the perinatal period. At age 1 year, three 
babies in the shunt group had required orchidopexy and 
one a vesicostomy; two underwent repeat valve resection, 
one a nephrostomy, and one a nephrectomy. Table 5 lists 
the complications of the vesicoamniotic shunt intervention. 
Total pregnancy losses were four of 15, although one of 
these losses was thought to be unrelated to treatment.
For our Bayesian analysis, the survey questionnaire was 
emailed to 248 experts, from whom 59 replies were 
received, seven of which were too incomplete to be 
included. Thus 52 experts provided information about 
their beliefs for change in perinatal mortality from 
intrauterine vesicoamniotic shunting. Although the 
experts generally supported the notion that shunting 
improved 28-day survival (the elicited probability of 
survival increasing was 79%), they were collectively 
sceptical about the ability of shunting to provide a 
treatment eﬀ ect as large as that anticipated by the trial (ie, 
an RR of 1·55). The elicited probability that the treatment 
eﬀ ect would be this large was only 15% (ﬁ gure 2A).
Uncertainty about the size of the treatment eﬀ ect 
remained when the elicited opinions were combined with 
the trial results (ﬁ gure 2B). The probability of survival 
increasing with vesicoamniotic shunting rose to 86% and 
the probability that VAS had a large, clinically important 
eﬀ ect (an increase in the proportion of babies who 
survived to 28 days of 55% or more) rose to 25%. Some 
uncertainty remained (probability 14%) about whether 
shunting might decrease survival. Analysis with the non-
informative prior showed a larger uncertainty about the 
treatment eﬀ ect than did analysis with the informative 
prior (ﬁ gure 2C), but with a much higher probability 
(67%) of survival improving by more than 55%.
Survival analysis of outcomes and partitioning by 
survival to 36·5 weeks and from 36·5 weeks to 5·7 years 
suggest that vesicoamniotic shunting could have harmful 
eﬀ ects from conception to 36·5 weeks (HR 0·90, 95% 
CrI 0·25–3·06), with only a 19% probability of the HR 
being greater than 1·55. However, from 36·5 weeks 
onwards some evidence suggests that shunting might 
increase survival outcomes, conditional on survival to 
36·5 weeks (4·20, 0·86–33·07), with a probability of 88% 
of the HR being greater than 1·55 (ﬁ gure 3).
Discussion
Survival to 28 days, 1 year, and 2 years seems to be higher 
in fetuses that received vesicoamniotic shunting, but 
uncertainty remains about the direction and size of the 
eﬀ ect such that beneﬁ t cannot be conclusively proven. 
However, overall outlook in both trial groups at 2 years 
was poor, with only two babies surviving to that age 
without renal impairment. This ﬁ nding reinforces the 
fact that the natural pathogenesis of this fetal disease is 
severe and that mortality and morbidity are substantial 
independent of treatment (panel).17
Even if perinatal survival is increased, vesicoamniotic 
shunting might not have a long-term beneﬁ t. Some of the 
women in the trial did not receive the allocated treatment 
because of clinician choice or a changing clinical situation. 
Few women were willing to consider participation in the 
trial and chose either entry onto the registry or termination 
of pregnancy. Among the trial participants, all perinatal 
survivors had abnormalities conﬁ rmed as secondary to 
congenital bladder outﬂ ow obstruction (posterior urethral 
valves and atresia). A high proportion of fetuses were at a 
gestational age of less than 24 weeks and had ultrasound 
features consistent with an overall poor outlook.10 This 
subgroup seemed to beneﬁ t most from vesicoamniotic 
shunting in our systematic review and subsequent meta-
analysis of perinatal outcomes.15
The trial was stopped early because of poor recruitment. 
Results are available for all babies until at least age 2 years. 
After 4 years, 144 women overall had been involved in the 
study (randomly assigned in the trial, registered, or 
terminations of pregnancy). The prevalence of LUTO 
overall was as previously reported,17 but the prevalence of 
isolated, antenatally detected LUTO amenable to inter-
vention was reduced.
A high proportion of pregnancies were lost (termination 
or intrauterine death) in both study groups and pregnancy 
outcomes (livebirths) did not diﬀ er signiﬁ cantly between 
the groups. However, survival to 28 days (perinatal and 
neonatal survival) seemed to be higher with vesicoamniotic 
shunting, but this result was not signiﬁ cant. On the basis 
of the expert (informative) and vague (non-informative) 
priors respectively, the Bayesian analysis gave estimated 
probabilities of 86% and 92% that shunting increased 
survival, and of 25% and 67% that the increase is greater 
than 55%. These ﬁ ndings are therefore in keeping with 
the results of our group’s systematic review of outcomes 
from case-cohort studies.27 Because all neonatal deaths in 
the trial were from pulmonary hypoplasia, the reduction 
in perinatal mortality noted with shunting is probably due 
to prevention or amelioration of the oligohydramnios at 
the crucial time of lung development (canalicular phase, 
between 16 and 24 weeks’ gestation).
Clinical outcomes at 1 and 2 years show an overall poor 
outlook in both groups, but again with a possible improved 
survival with shunting. The likelihood of surviving with 
normal renal function was very small in both groups, 
which suggests that the damage to the renal parenchyma 
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had already taken place at the time of diagnosis and was 
irreversible. Again, these ﬁ ndings are consistent with the 
meta-analysis results27 for postnatal survival with normal 
renal function from small cohort studies.
Another important ﬁ nding of the PLUTO trial was the 
high proportion of women who did not receive their 
allocated treatment. This crossover occurred either 
because of clinician choice or because of changing 
clinical features as the pregnancy progressed. Analysis 
on the basis of treatment received showed larger diﬀ er-
ences in outcome between the shunt and conservative 
management groups. For survival at 28 days and at 1 and 
2 years post-delivery, the outcomes favoured shunting 
and the diﬀ erences were signiﬁ cant. No diﬀ erence in 
survival with normal renal function was seen at 28 days 
or at 1 or 2 years in the as-treated analysis. However, 
because treatment selection was partly informed by 
outlook in this analysis, these ﬁ ndings could be con-
founded by selection bias.
The PLUTO trial showed that in the context of an 
intervention for a rare, fetal disease, few women (or 
their families) were willing to take part in a randomised 
trial of treatment and chose either entry onto the registry 
(in which case they or their health professional could 
choose treatment) or, more often, chose to terminate the 
pregnancy. Entry onto the registry was also common-
place because clinicians were not in clinical equipoise 
(ie, they were not substantially uncertain with respect to 
the best management option). The ﬁ ndings from the 
PLUTO registry will be reported in the UK National 
Institute of Health Research Health Technology Assess-
ment monograph.21
An important limitation of this trial is that the small 
number of pregnant women recruited made the study 
underpowered. For this reason, the trial was only 
suﬃ  ciently powered to detect very large diﬀ erences in the 
primary outcome. However, inclusion of a preplanned 
Bayesian analysis did allow direct estimation of the 
probability of beneﬁ t to assist decision making, even 
though conventional methods did not reach signiﬁ cance. 
One of the major barriers to recruitment was the high 
proportion of women entered onto the registry. Such a 
decision was often due to the treating clinician apparently 
not being in equipoise with respect to the beneﬁ ts of the 
intervention, which contrasts with the ﬁ ndings of the 
expert opinions elicited at the start of the study (wherein 
diverse opinions and apparent equipoise was seen, 
despite the ﬁ ndings of our group’s earlier systematic 
review15). This issue suggests a divergence of opinion 
between specialists and established clinical equipoise. A 
strength in this respect is that all children completed 
follow-up assessment and no data were missing for the 
primary and secondary endpoints. All endpoints were 
assessed independently by paediatric neonatologists and 
nephrologists as part of routine practice. The primary 
analysis was done on an intention-to-treat basis with no 
exclusions.
Allocation could not be masked from fetal medicine 
specialists, parents, or endpoint assessors because of the 
nature of the intervention. Because the primary endpoint 
was survival, the results for the primary outcome would 
not have been aﬀ ected by the absence of masking. 
However, this feature of the study design might have had 
an eﬀ ect on the number of women who crossed over from 
the conservative management to the shunt group because 
of a change in the assessment of the clinical situation as 
the pregnancy progressed. This selection bias will have 
been a confounder and the size and direction of its eﬀ ect 
cannot be assessed. Thus, the number of women who 
crossed over from conservative management to shunting 
limits the conclusions that can be drawn from the study.
Some researchers consider Bayesian analyses to be 
subjective, since they are dependent on the experts who 
agree to participate and whose opinions form the basis 
of the informative priors. The best way in which to 
elicit prior opinions so as to accurately reﬂ ect beliefs is 
also a heavily debated topic. Such analyses are also 
prone to convergence issues, although these issues 
tend to occur in more complicated models than those 
used in our analysis.
PLUTO is the only randomised controlled trial to 
investigate the eﬀ ectiveness of vesicoamniotic shunting 
in LUTO. We therefore cannot directly compare our 
results with previous work in terms of strengths and 
limitations. Although the number of participants 
recruited to PLUTO was small with respect to the 
prospective power calculation for the trial, it is similar to 
the numbers included in previously reported cohort 
studies. These retrospective case-cohort studies and their 
results have been rigorously assessed by our group via 
systematic review and meta-analysis as part of the 
PLUTO study, reported during the recruitment period.15,27 
The results from this systematic review suggest an OR 
for perinatal survival with vesicoamniotic shunting of 
Panel: Research in context
Systematic review
We used our previous systematic reviews15,27 to asssess the 
existing evidence about vesicoamniotic shunting for fetal 
lower urinary tract obstruction. The results of the most recent 
review27 suggest an odds ratio for perinatal survival with 
vesicoamniotic shunting of 3·86 (95% CI 2·00–7·45) and for 
survival with normal renal function of 0·50 (0·13–1·90). 
The evidence from observational studies suggests that 
vesicoamniotic shunting improves perinatal survival, but the 
eﬀ ect on long-term renal function is unclear.
Interpretation
The results of the PLUTO randomised controlled trial are 
consistent with the ﬁ ndings of the observational evidence for 
perinatal survival, but suggest that the chance of newborn 
babies surviving with normal renal function is very low 
irrespective of whether or not vesicoamniotic shunting is done.
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3·86 (95% CI 2·00–7·45) and for survival with normal 
renal function of 0·50 (0·13–1·90). The conclusion from 
the observational evidence is that shunting improves 
perinatal survival, but the eﬀ ect on long-term renal 
function is unclear. As an additional qualiﬁ cation, the 
outcome measures used for renal function in these 
observational studies were heterogeneous.
Because the ﬁ ndings of the PLUTO trial were limited 
by the small numbers of participants recruited, any 
recommendations should be interpreted with this 
limitation in mind. However, the results of the PLUTO 
trial are consistent with the observational evidence, 
which suggests that vesicoamniotic shunting improves 
overall perinatal survival, but that the long-term outlook 
for these babies is poor, with high mortality and 
morbidity. Parents should be counselled about the risks 
of pregnancy loss with or without shunt insertion. In the 
UK, the relevant National Institute for Health and Care 
Excellence interventional procedure guidance28 should be 
updated to take account of this new evidence.
Since PLUTO was a multicentre, international trial and 
did not recruit the necessary number of women to 
achieve adequate statistical power, a further randomised 
controlled trial is unlikely to be feasible. The babies 
recruited into the PLUTO trial must be prospectively 
followed up throughout childhood to attempt to assess 
the eﬀ ects of vesicoamniotic shunting on outcomes such 
as renal function, incontinence, cognitive development, 
and quality of life. However, the number of children who 
survive to a suitable age (2–5 years) is likely to be small.
Further research is needed to try to overcome the barriers 
to recruitment identiﬁ ed in this study—namely, the 
methods of randomised controlled trials in rare diseases 
(especially diseases related to pregnancy). Improvements 
have already been made in the past few years in the UK 
with respect to ethics and research and development 
approval for studies recruiting from several sites. These 
changes greatly reduced the time that centres took to 
recruit their ﬁ rst participants in the later period of the 
PLUTO trial. However, the study was limited in its ability 
to recruit by diﬃ  culties in obtaining indemnity and thus 
sponsorship for international centres. This issue is 
something that the international academic community, 
higher education institutions, and funders must work 
hard to resolve, so that research questions can be 
adequately addressed in the study of rare disease.
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